Aim: Sorafenib is the recommended standard of care for advanced hepatocellular carcinoma (HCC) patients. However, hepatic arterial infusion chemotherapy (HAIC) is a treatment option in Asia. We recently developed the assessment for continuous treatment with HAIC (ACTH) score to guide decision-making for continuous HAIC treatment. The purpose of this study was to validate the utility of the ACTH score in a dedicated cohort.
INTRODUCTION
H EPATOCELLULAR CARCINOMA (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. 1 Recent advances in treatment techniques, including hepatic resection, percutaneous ethanol injection, radiofrequency ablation, transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), sorafenib administration, and liver transplantation, have improved the prognosis of this type of malignancy. [2] [3] [4] [5] [6] [7] Transcatheter arterial chemoembolization is the standard of care for intermediate-stage HCC and is used worldwide. Measures such as the assessment for re-treatment with TACE, hepatoma arterial-embolization prognostic, selection for transarterial chemoembolization treatment and ABCR (staging for alpha-fetoprotein [AFP], Barcelona Clinic Liver Cancer stage, Child-Pugh score, and response) scores have been reported to be effective for judging TACE eligibility and are considered useful for prognostic stratification. [8] [9] [10] [11] For patients with advanced HCC who are not eligible for TACE, the multikinase inhibitor sorafenib is the currently recommended standard of care; 12 however, the response rate is low at approximately 2-3%. 7, 13 In contrast, HAIC (a recommended treatment for advanced HCC patients in Japan 14 and used in Asia) has a high response at approximately 30-40%; survival is significantly improved in radiological HAIC responders than in HAIC nonresponders. [15] [16] [17] Because of the poor prognosis of HAIC non-responders, it is important to identify patients likely to benefit from continuous HAIC treatment.
Recently, we developed the assessment for continuous treatment with HAIC (ACTH) score to guide decisionmaking for continuous HAIC treatment. 18 The ACTH score incorporates three commonly used factors (the ChildPugh score before HAIC and changes in both AFP and des-γ-carboxy prothrombin [DCP] levels), and is assessed at the mid-cycle of HAIC (i.e., 2 weeks after HAIC induction). This is a novel, simple, point-based score that stratifies patients according to prognosis; we found that the median survival times (MSTs) for patients with ACTH scores of ≤1 versus ≥2 points were 15.1 versus 8.7 months, respectively (P = 0.003). However, because only a training cohort was evaluated in our earlier study, a validation study was required. Therefore, we undertook this study to evaluate the efficacy of the ACTH score in a validation cohort. Additionally, we evaluated the utility of this score from the perspective of liver function during and after HAIC.
METHODS

Patients
B
ETWEEN JULY 1997 and July 2015, HAIC based on low-dose 5-fluorouracil/cisplatin (FP) was given to 171 patients who were admitted to our hospital with unresectable HCC. One hundred and thirty-one patients with elevated baseline levels of AFP (≥20 ng/mL) and/or elevated baseline levels of DCP (≥40 mAU/mL) were enrolled in this study. We developed the ACTH score based on the analysis of a training group between July 1997 and July 2012; 18 this training group included 90 patients who met the criteria for tumor markers. Next, we validated this scoring system using a validation cohort in a study carried out between August 2012 and July 2015; all 41 patients in this group had abnormal tumor marker levels. Hepatocellular carcinoma was considered unresectable in cases of bilobar disease, extrahepatic metastasis, portal vein tumor thrombosis, or locally advanced disease that was too extensive to undergo resection. A diagnosis of HCC was based on imaging results and elevated serum levels of AFP and/or DCP. We assessed tumor stage according to the criteria of the Liver Cancer Study Group of Japan, 6th edition. 19 This study (H28-002) was approved by the Institutional Review Board of Yamaguchi University Hospital (Ube, Japan). The protocol was carried out according to the principles of the 1975 Declaration of Helsinki.
Catheter placement
We inserted a heparin-coated 5-Fr catheter (Anthron P-U Catheter; Toray Medical Co. Ltd., Tokyo, Japan; or Piolax W spiral catheter; Piolax, Kanagawa, Japan) into the femoral, subclavian, or brachial artery. The tip of the catheter was positioned in the hepatic or gastroduodenal artery. The opposite end of the catheter was connected to the injection port, and the device was implanted under the skin. The gastroduodenal and right gastric arteries were occluded with steel coils to prevent gastroduodenal injury due to the anticancer agents. To prevent obstruction of the catheter, 5 mL (5000 U) heparin solution was injected every 2 weeks.
Chemotherapeutic regimen
As previously reported, 18 the chemotherapeutic regimens used in the training group were not uniform, even though all the regimens were based on low-dose FP. Of the 90 patients, 2 were treated with HAIC using low-dose FP, 20, 21 62 were treated with HAIC using low-dose FP and isovorin, 22 15 were treated with combination therapy consisting of low-dose FP, isovorin, and s.c. interferon (IFN)-α-2b, 23 and 11 were treated with combination therapy consisting of low-dose FP, isovorin, and s.c. pegylated IFN-α-2b. 24 In the validation group, all 41 patients were treated with HAIC using low-dose FP and isovorin.
One course of chemotherapy consisted of 5 consecutive days (days 1-5) of daily cisplatin (10 mg/body), followed by 5-fluorouracil (250 mg/body). Isovorin (6.25 mg/ body) was given daily on days 1-5. This course was repeated for 2 weeks, suspended for 1 week, and then repeated again for 2 weeks. In one treatment cycle, arterial infusion chemotherapy was given 20 times. Both cisplatin and 5-fluorouracil were administered using a mechanical infusion pump set at 1 h and 5 h, respectively. Isovorin was administered at 10 min. The serotonin antagonist ondansetron hydrochloride (4 mg) was given i.v. as an anti-emetic agent.
Evaluation of treatment response, tumor markers, and Child-Pugh score
The evaluation of the response to treatment was classified according to the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 25 based on dynamic computed tomography or magnetic resonance imaging carried out before and after one course of HAIC. Patients who had not completed the first cycle of therapy were regarded as having progressive disease (PD) if radiological disease progression was confirmed at that time. The response rate was calculated as the number of patients showing complete response (CR) and partial response (PR) divided by the total number of patients.
The AFP and DCP serum levels were measured using the LiBASys automated immunologic analyzer (Wako Pure Chemical Industries Ltd., Osaka, Japan). Both were obtained at baseline (prior to the administration of HAIC) and 2 weeks after the initiation of HAIC (i.e., after half a course of HAIC). A positive response was defined as a reduction of ≥20% from baseline 26, 27 whereas a nonresponse was defined as a <20% reduction from baseline or an increase (into the abnormal range) from the baseline of AFP or DCP levels after half a course of HAIC. Additionally, we calculated the Child-Pugh score at three time points (before HAIC, 2 weeks after HAIC induction, and after the completion of one course of HAIC).
Assessment for continuous treatment with HAIC score
We developed the ACTH score, which ranges from 0 to 3, using the training group (Table 1) . 18 This point score is calculated as follows: Child-Pugh score before HAIC (A = 0, B = 1), AFP response (yes = 0, no = 1), and DCP response (yes = 0, no = 1). A change in the normal range of AFP and DCP between baseline and half a course of HAIC is assigned a score of 0.
Statistical analysis
Data are expressed as the mean ± standard deviation. Statistical analysis of categorical data was carried out using the χ 2 -test or Fisher's exact test. Overall survival was calculated using the Kaplan-Meier method. Survival time was defined as the interval between the first HAIC session and the last follow-up visit or death; the follow-up period ended on February 29, 2016. Statistical significance was defined as a P-value <0.05. All analyses were undertaken using the JMP version 10.0 software package (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
T HE CLINICAL PROFILES of 90 patients in the training group and 41 in the validation group are summarized in Table 2 . In the training group, the patient population comprised 75 men and 15 women, with a mean age of 65.7 years (range, 44-85 years). Among 90 patients, 8 (8.9%), 19 (21.1%), and 63 (70.0%) had elevated levels of AFP, DCP, or both of these tumor markers, respectively. The clinical observation period following the completion of HAIC treatment ranged from 42 to 4597 days.
The patients of the validation group comprised 31 men and 10 women, with a mean age of 65.9 years (range, 35-85 years). Among these 41 patients, 3 (7.3%), 4 (9.8 %), and 34 (82.9%) had elevated levels of AFP, DCP, or both, respectively. The clinical observation period following completion of HAIC treatment ranged from 27 to 985 days.
There were no significant differences in patient characteristics except the etiology of HCC between the two groups; there were significantly fewer HCC patients with hepatitis C virus in the validation group than in the training group (P = 0.008). In the training group, 46 patients (51.1%) had ACTH scores ≤1 and 44 (48.9%) had scores ≥2. In the validation group, 21 patients (51.2%) had ACTH scores ≤1 and 20 (48.8%) had scores ≥2.
Response to therapy
The responses to therapy are summarized in Table 3 18 With respect to AFP levels, the treatment response rates among 37 validation group patients were 44.4% among AFP responders and 21.4% among AFP non-responders (P = 0.215). There were no significant differences in clinical characteristics between AFP responders and nonresponders (Table S1 ). As for DCP levels, the treatment response rates among 38 evaluated patients were 42.9% in DCP responders and 0.0% in DCP non-responders (P = 0.002). There were no significant differences in clinical characteristics between DCP responders and nonresponders (Table S2) . 1 †α-Fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) responses were assessed after half a course of hepatic arterial infusion chemotherapy (2 weeks). A positive response was defined as a reduction of ≥20% from baseline.
Patient survival
The overall survival rates in the validation and the training groups are shown in Figure S1 ; no significant difference was observed (MST, 10.3 vs. 10.6 months, respectively; P = 0.833). Patients in the validation group were stratified into two subgroups according to the ACTH score (≤1 vs. ≥2); these subgroups comprised of 21 (51.2%) and 20 (48.8%) patients, respectively. The MST was longer in patients with an ACTH score of ≤1 (15.9 months) than in those with a score of ≥2 (7.0 months, P = 0.002) (Fig. 1) . Additionally, the overall survival rates in patients within each of the ≤1 versus ≥2 ACTH score subgroups were similar in the validation and training groups (Fig. S2 ). 
Relationship between ACTH score and response to therapy
We evaluated the relationship between the ACTH score (≤1 and ≥2) and response to therapy in both the training and validation groups. Among patients with an ACTH score of ≤1 (67 patients), 33 showed radiological response (Fig. 2a) ; 80.5% of all HAIC responders (33/41 patients) had ACTH scores of ≤1 (Fig. 2b) . Among patients with an ACTH score of ≥2 (64 patients), 56 showed radiological non-response; as such, 87.5% of patients with a score of ≥2 (56/64) were HAIC non-responders (Fig. 2a) .
Overall survival predicted by ACTH score
We evaluated overall survival in both the training and validation groups according to patients' ACTH scores: 0 (n = 17), 1 (n = 50), 2 (n = 49), and 3 points (n = 15). Patients were significantly stratified according to the ACTH score; the MSTs of patients with ACTH scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months (score of 0 vs. 1, P = 0.085; score of 1 vs. 2, P = 0.044; and score of 2 vs. 3, P < 0.001), respectively (Fig. S3) .
Change of liver function during and after the procedure
Of all 131 patients, 41 and 90 were deemed to be HAIC responders (CR/PR) and non-responders (SD/PD) after one course, respectively. Among responders, most patients did not show a deterioration of liver function after one course of HAIC (35/36 patients, 97.2%) (Fig. 3a,b) . Interestingly, some patients improved their Child-Pugh classification from B to A, 2 weeks after HAIC (7/19 patients, 36.8%) or after one course of HAIC (5/18 patients, 27.7%) (Fig. 3b) . Among patients with ChildPugh B before HAIC, Child-Pugh class was significantly improved in HAIC responders (2 weeks after HAIC, P = 0.026; after one course of HAIC, P = 0.046), but not in non-responders (Fig. 3b,d ). Among non-responders, Figure 1 Assessment for continuous treatment with hepatic arterial infusion chemotherapy (ACTH) score stratified according to prognosis in the validation group. Patients with advanced hepatocellular carcinoma were stratified into two groups according to the ACTH score (≤1 vs. ≥2 points). These groups showed significantly different prognoses with median survival times (MSTs) of 15.9 versus 7.0 months, respectively; P = 0.002. Two of 42 patients (4.8%) and 5 of 42 patients (11.9%) dropped from Child-Pugh B to C classification 2 weeks after HAIC and after one course of HAIC, respectively. *HAIC non-responders with Child-Pugh A before HAIC tended to experience deterioration of liver function during and after HAIC (2 weeks after HAIC, P = 0.068; after one course of HAIC, P = 0.105). **Significant differences in Child-Pugh scores during and after HAIC between HAIC responders and non-responders who were of Child-Pugh B classification before HAIC (2 weeks after HAIC, P = 0.026; after one course of HAIC, P = 0.046).
48 and 42 patients had Child-Pugh A and Child-Pugh B before HAIC, respectively, and 15 of 90 patients (16.7%) experienced liver function deterioration after one course of HAIC (Fig. 3c,d ). For non-responders with ChildPugh A before HAIC, 5 and 10 patients dropped from Child-Pugh A to B, 2 weeks after HAIC (5/48 patients, 10.4%) and after one course of HAIC (10/48 patients, 20.8%), respectively. There were 67 and 64 patients in the ACTH score ≤1 and ≥2 groups, respectively. Changes in Child-Pugh scores in patients with ACTH score ≥2 were similar among those who were HAIC non-responders (Fig. S4) .
DISCUSSION
T HE PROGNOSIS OF advanced HCC, especially in the presence of vascular invasion and/or extrahepatic spread, remains poor. In Japan, patients with advanced HCC who did not receive active therapy achieved an MST of 5.2 months. 28 For such patients, sorafenib is recognized as the current standard of care worldwide, 12 although HAIC is offered as a treatment option in Asia. 14, 28, 29 However, there are no established criteria for selecting advanced HCC patients who should receive either HAIC or sorafenib; this inspired us to develop the ACTH score. 18 Although there are many scoring systems with respect to TACE, [8] [9] [10] [11] ours is the first aimed towards the therapeutic assessment of candidates for HAIC.
Des-γ-carboxy prothrombin response to HAIC treatment was significantly associated with treatment response in the validation group, but AFP response was not. We previously reported that DCP response is the sole independent predictor for assessing early treatment response to HAIC; 18 our current findings are consistent with our earlier results.
There was no significant difference between the validation and training groups in terms of survival; MSTs were 10.3 and 10.6 months, respectively (Fig. S1) . Although there was a significant difference in the etiology of HCC, this may be attributed to the different time periods in which each cohort was tested. 30 Dividing patients by ACTH scores of ≤1 versus ≥2 points produced almost equal-sized groups receiving HAIC. However, the prognoses were significantly different, with MSTs of 15.9 months versus 7.0 months (P = 0.002) for patients with ACTH scores ≤1 and ≥2, respectively, in the validation group (Fig. 1) . These results validate the usefulness of this scoring system. Furthermore, each of the individual ACTH scores identified a distinct group of patients with different prognoses; that is, patients with ACTH scores of 0, 1, 2, and 3 points showed MSTs of 21.7, 14.4, 9.5, and 3.8 months, respectively (Fig. S3) . Our analysis did not show the differences in survival times between patients with scores of 0 versus 1 point to be significant; however, the prognoses of patients with 2 points were significantly poorer compared with those of patients with 1 point. These findings indicate that the ACTH scoring system is a reasonable criterion for treatment stratification.
We investigated the relationship between the ATCH score and response to therapy. Among patients with a score of ≤1, 49.3% and 50.7% were classified as HAIC responders and non-responders, respectively (Fig. 2a) . Although the ACTH score was developed based on predictors of survival after HAIC, it may possibly be utilized to predict treatment responders (Fig. 2b) . Among patients with a score of ≥2, 12.5% and 87.5% were classified as HAIC responders and non-responders, respectively (Fig. 2a) . As the majority of patients with ACTH scores ≥2 were HAIC non-responders (87.5%), a second-line therapy should be considered for those with ACTH scores ≥2. Furthermore, all 8 responders (i.e., those with PR) in the ACTH score ≥2 group had Child-Pugh B status. Interestingly, the MST was significantly shorter in responders with scores of ≥2 (11.8 months) than in those with scores of ≤1 (21.7 months, P = 0.027) (Fig. S5a) ; however, MSTs were not different among non-responders in either ACTH score groups (Fig. S5b) . These findings indicated that the ACTH score may be useful for estimating prognosis in HAIC responders; however, further investigations are necessary in larger populations.
Terashima et al. reported that the Child-Pugh score of HAIC responders with Child-Pugh B was significantly improved after HAIC, 31 consistent with our results. We showed that liver function significantly improved for HAIC responders with Child-Pugh B during HAIC; however, some HAIC non-responders experienced deteriorated liver function during and after HAIC regardless of Child-Pugh status before HAIC (Fig. 3c,d) . Next, we evaluated liver function during and after HAIC between patients with ACTH scores ≤1 and those with scores ≥2. As expected, changes in liver function in those with scores ≥2 were strongly correlated with those among HAIC non-responders. Focusing on candidates for sorafenib, which is generally used to treat patients with Child-Pugh A, we devised a simulation showing the difference in treatment strategies for advanced HCC after the initiation of HAIC (Fig. 4) . Figure 4a shows our conventional treatment strategy for advanced HCC after initiating HAIC; Figure 4b shows a new treatment strategy based on the ACTH score. Several researchers have shown that survival is significantly improved in radiological HAIC responders (CR/PR) than in HAIC non-responders (SD/PR). [15] [16] [17] In our study, the MST was longer in HAIC responders (18.1 months) than in HAIC non-responders (7.3 months, P < 0.001). Although there was a significant difference in survival between patients with SD and those with PD in a previous report (SD, 9.5 months; PD, 6.0 months; P < 0.0001) 28 and this study (SD, 9.6 months; PD, 5.0 months; P = 0.009), we consider that it is preferable to switch to other treatments, such as sorafenib, for non-responders because HAIC treatment aggravates the patient's quality of life compared with oral agents. In our conventional treatment strategy, we consider other treatments for non-responders after one course of HAIC, according to radiological evaluation; the total number of candidates for sorafenib was 42 non-responders (Fig. 4a) . In the proposed treatment strategy, the ACTH score and radiological evaluation are undertaken in two steps: mid-course through HAIC treatment (2 weeks) and after the completion of one course, following which we would consider other treatments for patients with scores of ≥2 and for non-responders, respectively. Twenty-eight of 64 patients with scores of ≥2 were candidates for sorafenib at the first step, and 22 of 34 non-responders were candidates for sorafenib at the second step; the total number of candidates for sorafenib was 50 patients (Fig. 4b) . Hence, using the ACTH score method increased the number of candidates for sorafenib from 42 to 50 patients. As this score facilitates the early detection of many non-responders (62.2% in this study), other treatments such as sorafenib could be introduced before liver function deteriorates.
There are some limitations in this study. First, it was undertaken at a single institution with a small patient group. The usefulness of the ACTH score was nevertheless validated. Second, the ACTH score was determined in HCC patients who received non-uniform HAIC regimens (the training group); this limitation was stated in our previous report. 18 In the validation group, however, HCC patients were treated with a uniform regimen. The ACTH score may also be useful for HCC patients treated with other HAIC regimens. In the future, additional validation is warranted at other institutions and in patients who were treated with other HAIC regimens. Finally, this score cannot be used for patients with normal levels of both AFP and DCP. However, high tumor marker levels are associated with advanced HCC; 32 indeed 131 of the 171 patients who received HAIC (77%) were eligible for this study. In particular, all recently treated patients among those in the validation group showed abnormal levels of either AFP or DCP.
In conclusion, we validated our previously described ACTH score in a dedicated cohort. The ACTH score can therefore aid in the therapeutic assessment and continued treatment planning of HCC patients receiving HAIC.
SUPPORTING INFORMATION
A DDITIONAL SUPPORTING INFORMATION may be found online in the supporting information tab for this article.
Table S1
Characteristics of patients with elevated α-fetoprotein (AFP) at baseline Table S2 Characteristics of patients with elevated des-γ-carboxy prothrombin (DCP) at baseline Fig S1 Cumulative survival of patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy in the validation and training groups. The prognoses were not significantly different between the two groups; the median survival times in the validation and training groups were 10.3 and 10.6 months, respectively; P = 0.833. Fig S2 (a) Cumulative survival rates in patients in the validation and training groups with assessment for continuous treatment with hepatic arterial infusion chemotherapy (ACTH) scores ≤1. There was no significant survival difference between the validation and training groups (median survival times [MSTs], 15.9 and 16.5 months, respectively; P = 0.878). (b) Cumulative survival rates in patients of the validation and training groups with ACTH scores ≥2. There was no significant difference between the two groups (MST, 7.0 and 9.4 months, respectively; P = 0.529). Fig S3 Assessment for continuous treatment with hepatic arterial infusion chemotherapy (ACTH) score predicts overall survival. Significant survival differences were observed in patients stratified according to the ACTH score. The median survival times for patients with ACTH scores of 0, 1, 2, and 3 points were 21.7, 14.4, 9.5, and 3.8 months, respectively. Evaluation
